Wilson Therapeutics (publ) announces that management will present at the following upcoming international investor conferences:
Cowen & Company 38th Annual Healthcare Conference, Boston
Monday, March 12, 2018 – presentation at 2:10 p.m. ET (20:10 CET) in Salon C, 4thFloor, Boston Marriott Copley Hotel
Presenter: Jonas Hansson, Chief Executive Officer
A live audio webcast of the presentation will be available and can be accessed at www.wilsontherapeutics.com, under Media & Investors / Presentations
Stifel Nordic Healthcare Seminar, London
Tuesday, March 20, 2018 – presentation at 11:15 a.m. GMT (12:15 CET)
Presenter: Jonas Hansson, Chief Executive Officer
Further information about upcoming events and presentations, including Wilson Therapeutics’ Capital Markets Day on March 21, 2018, can be found on the Company’s website.
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information please contact:
Lauren Williams, Head of Investor Relations, Wilson Therapeutics AB
Phone: +44 7958 669 896
E-mail: lauren.williams@wtx.se
Wilson Therapeutics AB (publ)
Corp. Reg. No.556893-0357
Kungsgatan 3
SE-111 43 Stockholm
The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on 6 March, 2018.
